A young female patient with occlusive vascular disease;Junge patientin mit multiplen arteriellen verschlussen

Medizinische Klinik

Volumn 93, Issue 5, 1998, Pages 311-318

  Panzer, Claudia ^a,d   Brieke, Andreas ^a   Bräuer, Burkhard ^a   Eggemann, Franz ^b   Becker, Hans Martin ^c   Dieterle, Peter ^a  

^a S

^b Abt F Rontgendiagnostik N

^c Abteilung fur Gefasschirurgie   (Germany)

^d 3 Med Abt F Endokrinol S   (Germany)

Author keywords

Arterial occlusive disease; Folate; Homocysteine; Vitamin B12; Vitamin B6

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULT; ANGIOGRAPHY; ARTICLE; CASE REPORT; CELIAC ARTERY; COLLATERAL CIRCULATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; ILEUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SUPERIOR MESENTERIC ARTERY; VASCULAR DISEASE;

EID: 0032523942     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044867     Document Type: Article

References (40)

1. Amatucci G. del Mastro G. Iandoli R Horton giant cell arteritis of the legs - report of a case. J Cardiovasc Surg 1997;38:309-12.
2. Andria G, Sebastio G. Homocystinuria due to cystathionine-β-synthase deficiency and related disorders. In. Fernandez, Saudubray, Beruhe van den., Inborn metabolic diseases, 2nd edn. Berlin-Heideiberg-New York. Springer, 1996 177-82.
3. Becker PJ, Ubbinck JB, Vermaak WJ, van der Merwe A. Vitamin B-12, vitamin B-6 und folate nutritional status in men with hyperhomocystemamie. Am J Clin Nutr 1993;57:47-53
4. Bergmark C, Mansoor MA, Svardal AM, Swedenborg J, Ueland PM, de Faire U. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50 - effect of smoking and extent of disease Eur J Vasc Surg 1993;7:391-6
5. Bick RL, Baker WF. The antiphospholipid and thrombosis syndromes Comm Bleed Clott Disorders 1994;78: 667-81.
6. Bienvenu T, Ankri A, Chadefaux B, Montalerscot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters, Thromb Res 1993;70:123-9.
7. Broeckaert L, Etcors N, Ponette E, et al. Mesenteric involvement of thromangutis obliterans (Buerger's disease) in a woman. J Belge Radiol 1993;76:245-6.
8. Chauveau P, Chadefoux B, CoudeM, Aupeatit J, Kamoun P, Jungers P. Long terni folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996;22:106-9.
9. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
10. Cravo ML, Gloria LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism correlation with folate, vitamin B12, and vitamin B6 status. Am J Clin Nutr 1996;63:220-4
11. Dahlback B. The protein C anticoagulant system. Inherited defects as basis for venous thrombosis. Thromb Res 1995;77 1-43.
12. Dahlback B, Hildebrand B. Inhented resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci LISA 1991,91:1396-1400
13. Diehm C, Stammler F. Thrombangutis obliterans (Buerger-Syndrom). Dtsch Med Wochenschr 1996;121:1543-8.
14. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurence, cofacor therapy and enzymology J Nutr 1996;126:1276S.
15. Fermo I, D'Angelo SV, Parom R, Mazzola G, Calori G, D'Angelo A Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease Ann Intern Med 1995;123 747-53.
16. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM. Kloppenborg PWC. Treatment of mild hyperhomocvsteinemia in vascular disease patients. Anerioscler Thromb. 1944;14 465-70.
17. Graham IM, Daly LE, Refsum HM, et al Plasma homocysteine as a risk factor tor vascular disease JAMA 1997,277 1775-81.
18. Harpel P, Zhang X Borth W. Homocysteine and hemostasis. pathogentic mechanisms predisposing to thrombosis J Nutr 1996;126:1285S-9S
19. Hunder G Vaskulitis: Diagnosis and therapy. Am J Med 1996,100,Suppl 2A 37S-45S
20. Jacques, PF, Bostom AC, Williams RR, et al Relation between folate status, a common mutation in methylenetetrahvdrofolat reductase, and plasma homocysteine concentrations Circulation 1996;93:7-9.
21. Joosten E, van den Berg A, Riezler R, et al Metabolic evidence that deficiencies of vitamin B12, folate and vitamin B6 occur commonly in elderly people Am J Clin Nutr 1993;58:468-76.
22. Kang SS Treatment of hyperhomocystememia J Nutr 1996;126 1273S-5S
23. Kang SS, Wong PW, Bock HG, Horwitz A. Grix A Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenctetrahydrofolate reductase mutations Am J Hum Gen 1991;48 546-51
24. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N Thermolablie methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Gen 1991;48:536-45
25. Malinow MR. Plasma homocyst(e)ine: A risk factor for arterial occlusive diseases. J Nutr 1996;126;1238S-43S.
26. Mc Cully KS. Vascular pathology of homocysteinemia: implications for pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
27. Molloy AM, Daly SD, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997;349:1591-3.
28. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine-β-synthase deficiency. AmJ Hum Genet 1985;37:1-31.
29. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346-85-9.
30. Nygard O, Vollset SE, Refsum H, Total plasma homocysteine and cardiovascular risk profile. The Hoordaland Homocysteine study. JAMA 1973;274:1526-33.
31. Ounel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg 1996;23:46-51.
32. Perry IJ, Refsum H, Morris R, Ebrahim SB, Ueland PM, Shaper AG Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
33. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate Common and independent reversible risk factor for coronary artery disease. Circulation 1995;92-2825-30.
34. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocystein-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16
35. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extra-cranial carotid-artery stenosis. N EnglJ Med 1995;332; 286-91.
36. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. Prävalenz der Hyperhornocysteinamie bei der Thrombangutis obhterans, Dtsch Med Wochenschr 1996;121: 1417-23.
37. Tazi Z, Cacoub P, Koskas F, et al. Value of an extensive biological study in venous or arterial thromboses. Presse Med 1996;25 531-6.
38. The European working group on critical limb ischaemia: Second European consensus document on chronic critical leg ischemia. Circulation 1991;84:Suppl:IV-1-IV-22.
39. Ubbink JB, van der Merwe A, Vermmak WJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993;71:993-8.
40. van den Berg M, Franken DG, Boers GHJ, et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994;20:933-4.